Skip to main content
letter
. 2020 Jun 15;18(11):2633–2637. doi: 10.1016/j.cgh.2020.06.011

Figure 1.

Figure 1

Temporal liver function test of cases A–E during hospitalization. (A) In patient A (male, 51 y; hepatitis B virus carrier, severe), AST and ALT levels increased to 3.2 times baseline in the first week and decreased to near normal on day 14 after admission with the use of liver-protecting drugs. However, 5 days later, AST and ALT levels increased again to 3.2 and 4.0 times baseline, respectively. (B) In case B (male, 29 y; chronic hepatitis B, critically ill), AST and ALT levels increased to 2.7 and 13.7 times baseline at day 12 after admission, and then decreased with the use of liver-protecting drugs. In the last test, AST and ALT levels were 1.2 and 4.1 times baseline, respectively. (C) In case C (male, 64 y; hepatitis B virus carrier, severe), AST and ALT levels increased continuously to 6.9 and 13.6 times baseline, respectively. (D) In case D (male, 44 y; hepatitis B cirrhosis, critically ill), AST and ALT levels increased to 4.0 and 7.5 times baseline at day 12 after admission, respectively, and then decreased to 1.7 and 1.9 times baseline owing to the use of liver-protecting drugs. TBIL and DBIL stabilized at a higher level, exceeding the upper limit of normal value. (E) In case E (female, 47 y; hepatitis B virus carrier, severe), liver function tests of the patient were normal. ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; DBIL, direct bilirubin; GGT, γ-glutamyl transpeptidase; TBIL, total bilirubin.